期刊名称：Proceedings of the National Academy of Sciences
印刷版ISSN：0027-8424
电子版ISSN：1091-6490
出版年度：2021
卷号：118
期号：4
页码：1
DOI：10.1073/pnas.2020660118
出版社：The National Academy of Sciences of the United States of America
摘要：Our study (1) was designed to provide definitive direct data to the microglia community that PLX5622 does not act solely on microglia but also affects other peripheral macrophage populations. Many microglia papers have assumed or claimed that CSFR1 inhibition has no to minimal effects on peripheral immune cells.* The nonmicroglia effects of CSFR1 inhibition have direct ramifications for the interpretation of relevant experimental data; peripheral monocytes/macrophages engraft permanently into the retina after PLX5622 treatment (2, 3), causing remodeling and functional changes that affect studied outcome. We reject the comment by Green and Hume (4) that PLX5622 dose and duration was not provided or that it was selected arbitrarily. A careful reading of our paper (1) and the literature reveals this information, which is in concordance with at least 14 papers using exactly the same dose (PLX5622 chow, 1,200 ppm) and duration (3 wk) (1⇓–3, 5), some of which have been cited by Green et.
